Laurion Capital Management LP Travere Therapeutics, Inc. Transaction History

Laurion Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.26 - $8.28 $58,685 - $92,379	11,157 New	11,157 $91,000
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $2.67 Million - $3.43 Million	150,000 Added 17.96%	984,961 $22.2 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $708,127 - $1.01 Million	-33,817 Reduced 3.89%	834,961 $20.2 Million
Q1 2022 May 16, 2022	SELL	$23.61 - $30.6 $948,484 - $1.23 Million	-40,173 Reduced 4.42%	868,778 $22.4 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $3.65 Million - $4.68 Million	150,000 Added 19.76%	908,951 $28.2 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $2.49 Million - $4.8 Million	191,768 Added 33.81%	758,951 $18.4 Million
Q2 2021 Aug 13, 2021	BUY	$14.11 - $26.4 $4.29 Million - $8.03 Million	304,170 Added 115.65%	567,183 $8.28 Million
Q1 2021 May 14, 2021	BUY	$23.37 - $31.77 $6.15 Million - $8.36 Million	263,013 New	263,013 $6.57 Million

214

94.3M

1.2M

778K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.32B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.